Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
1. Moleculin has enrolled first two subjects in Spain for AML trial. 2. The pivotal MIRACLE trial aims to recruit 45 subjects by late 2025. 3. Initial data readout expected in the second half of 2025. 4. Annamycin holds Fast Track and Orphan Drug Designations from FDA. 5. The trial demonstrates urgent need in treating R/R AML patients.